KRAS and neoplasm: Through this first KRAS mutation landscape study of large sample size rare tumors in China and worldwide, we have found that KRAS mutation is common in rare tumors, with an overall mutation rate of 8.7% and a G12C mutation rate of 0.6%, with mutation rate and mutation subtypes varying widely across tumor systems and subtypes.